Developments for a growing Japanese patient population: Facilitating new technologies for future health care

Harubumi Kato, Toshihide Nishimura, Norihiko Ikeda, Tesshi Yamada, Tadashi Kondo, Nagahiro Saijo, Kazuto Nishio, Junichiro Fujimoto, Masaharu Nomura, Yoshiya Oda, Bertil Lindmark, Jiro Maniwa, Hitoshi Hibino, Michiaki Unno, Toshinori Ito, Yoshiki Sawa, Hiromasa Tojo, Shin Egawa, Goutham Edula, Mary LopezMurray Wigmore, Naohiko Inase, Yasuyuki Yoshizawa, Fumio Nomura, György Marko-Varga

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)


Lung cancer, COPD and cardiovascular diseases are highlighted as some of the most common disease that cause mortality, and for that reason are the most active areas for drug development. This perspective paper overviews the urgent need to develop a health care system for a rapidly growing patient population in Japan, including forthcoming demands on clinical care, expecting outcomes, and economics. There is an increasing requirement to build on the strengths of the current health care system, thereby delivering urgent solutions for the future. There is also a declaration from the Ministry of Health, Labour and Welfare (MHLW), to develop new biomarker diagnostics, which is intended for patient stratification, aiding in diagnostic phenotype selection for responders to drug treatment of Japanese patients.This perspective was written by the panel in order to introduce novel technologies and diagnostic capabilities with successful implementation. The next generation of personalized drugs for targeted and stratified patient treatment will soon be available in major disease areas such as, lifestyle-related cancers, especially lung cancers with the highest mortality including a predisposing disorder chronic obstructive pulmonary disease, cardiovascular disease, and other diseases. Mass spectrometric technologies can provide the "phenotypic fingerprint" required for the concept of Personalized Medicine. Mass spectrometry-driven target biomarker diagnoses in combination with high resolution computed tomography can provide a critical pathway initiative facilitated by a fully integrated e-Health infrastructure system.We strongly recommend integrating validated biomarkers based on clinical proteomics, medical imaging with clinical care supported by e-Health model to support personalized treatment paradigms to reduce mortality and healthcare costs of chronic and co-morbid diseases in the elderly population of Japan.

Original languageEnglish
Pages (from-to)759-764
Number of pages6
JournalJournal of Proteomics
Issue number6
Publication statusPublished - 2011 May 16


  • Biomarker
  • Chronic Obstructive Pulmonary Disease
  • Diagnosis
  • Lung cancer
  • Mass spectrometry
  • Proteomics

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry


Dive into the research topics of 'Developments for a growing Japanese patient population: Facilitating new technologies for future health care'. Together they form a unique fingerprint.

Cite this